We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
VCM
276
Versant Capital Management
Arizona
$1.46K +$561 +9 +64%
NC
277
NewSquare Capital
Pennsylvania
$1.27K – – –
AAP
278
Arax Advisory Partners
Colorado
$1.2K – – –
CPG
279
Cornerstone Planning Group
New Jersey
$1.2K +$1.18K +19 New
IA
280
IFP Advisors
Florida
$1.2K +$1.18K +19 New
EWA
281
EverSource Wealth Advisors
Alabama
$1.14K +$499 +8 +80%
QCG
282
Quadrant Capital Group
Ohio
$1.01K – – –
IFAM
283
Institutional & Family Asset Management
Colorado
$570 – – –
FSWA
284
Financial Synergies Wealth Advisors
Texas
$380 – – –
GWS
285
Glassman Wealth Services
Virginia
$317 +$312 +5 New
CJL
286
Cyrus J. Lawrence
New York
$224 – – –
FGAM
287
Financial Gravity Asset Management
Texas
$91 +$3.93K +63 New
DM
288
Deerfield Management
New York
– -$39.7M -734,000 Closed
Walleye Capital
289
Walleye Capital
New York
– -$14.1M -226,402 Closed
EP
290
Eversept Partners
New York
– -$11.8M -218,726 Closed
OCA
291
Octagon Capital Advisors
New York
– -$5.13M -94,700 Closed
GPP
292
Great Point Partners
Connecticut
– -$3.81M -70,371 Closed
LOAMS
293
Lombard Odier Asset Management (Switzerland)
Switzerland
– -$3.35M -61,882 Closed
Simplex Trading
294
Simplex Trading
Illinois
– -$2.64M -42,348 Closed
Walleye Trading
295
Walleye Trading
New York
– -$1.48M -27,318 Closed
Squarepoint
296
Squarepoint
New York
– -$1.42M -26,260 Closed
YIH
297
Y-Intercept (HK)
Hong Kong
– -$1.41M -25,982 Closed
MC
298
Miramar Capital
Illinois
– -$1.22M -22,550 Closed
Nomura Holdings
299
Nomura Holdings
Japan
– -$1.19M -21,909 Closed
BPC
300
Banque Pictet & Cie
Switzerland
– -$1.08M -20,000 Closed
9 10 11
12
13

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.